Tag:

Biogen Idec

Latest Headlines

Latest Headlines

Samsung and Biogen plot an IPO for their biosimilars JV

Samsung Bioepis, a joint venture between the South Korean conglomerate and Biogen, is planning a jump to the Nasdaq with eyes on raising cash to market cheaper copies of blockbuster biologics.

Which Big Biotechs join Gilead in Fortune's fastest-growing pharma ranks?

The company at the top of Fortune's fastest-growing-in-pharma list is just the one you'd expect: Gilead Sciences, with its hep C-fueled leap into the industry's top 10 by revenue. And it's no surprise that the next two are Big Biotech companies, given the ascendance of biologic meds. But one Big Pharma--and only one--managed to crack the top 5.

Insider traders cashed in on Biogen's $320M Sangamo deal, SEC says

Back in 2013, as Sangamo Biosciences negotiated what would become a sizable partnership deal, one of the company's officers leaked the news to a longtime friend, according to the SEC, setting in motion an insider trading scheme authorities say netted more than $1.2 million.

Hedge fund aims algorithms at pharma patents to sink stocks

Hedge fund manager Kyle Bass has outlined how he picks pharma patents to challenge for his new money-spinning project. The project is underpinned by two emerging assets commonly thought of as a potential boon for drug developers: large data sets and algorithms with which to interrogate them.

Back-to-'Biogen' shift signals wider industry branding trend

Biogen's recent change back to its original name--from the decade-old merger name Biogen Idec--made sense in many ways. Along with the nod to its biotech founding heritage, most people already called the company simply "Biogen," anyway. But the switch to just Biogen also signaled a new direction for the company and recognized the new reality in pharma.

Biogen CEO Scangos commits $2.5B to a high-stakes Alzheimer's gamble

How much does it cost to develop a new drug? In Biogen's case, the answer is $2.5 billion. That's the figure that CEO George Scangos gave to the World Medical Innovation Forum in Boston for its much-hyped Alzheimer's drug, according to Bloomberg 's Michelle Fay Cortez.

What price MS therapy? Thanks to price hikes, $50K-plus, even for decades-old meds

The cost of multiple sclerosis drugs has skyrocketed over the past 20 years, and it's not just new drugs driving that increase. Not one MS drug has a list price of less than $50,000 per year in the U.S., and some treatments cost 7 times more now than they did in 1995, a new study found.

Biogen sales, profit miss the mark as Tecfidera flags

Remember the days when Biogen's Tecfidera was trumping analyst expectation after analyst expectation? Well, they're in the past--at least for now.

Biogen blueprints a big Phase III effort for its Alzheimer's hopeful

Riding high on some promising Phase I data, Biogen has mapped out a big late-stage program for its Alzheimer's disease treatment, making a risky bet that it can reverse decades of failure in the field.

Attention pharma laggards: FitBit trackers delivered in Biogen's MS movement study

The wearable fitness trend has exploded in the past few years. But for patients with certain medical conditions, wearables are more than hipster status symbols. The devices could help them manage chronic conditions. And for pharma companies, they could gather data to help tailor new treatments, track patient outcomes, and develop relationships with the people who use their meds.